ES2075338T3 - Formulacion de naproxeno, de absorcion controlada, para administracion una vez al dia. - Google Patents
Formulacion de naproxeno, de absorcion controlada, para administracion una vez al dia.Info
- Publication number
- ES2075338T3 ES2075338T3 ES91300243T ES91300243T ES2075338T3 ES 2075338 T3 ES2075338 T3 ES 2075338T3 ES 91300243 T ES91300243 T ES 91300243T ES 91300243 T ES91300243 T ES 91300243T ES 2075338 T3 ES2075338 T3 ES 2075338T3
- Authority
- ES
- Spain
- Prior art keywords
- day
- formulation
- naproxeno
- naproxen
- once
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
UNA FORMULACION DEL NAPROXENO PARA LA ADMINISTRACION ORAL DE UNA VEZ AL DIA, QUE CONSTA DE UNA PRIMERA PARTE DEL NAPROXENO FORMULADO EN FORMA DE PILDORAS CON MULTIGRANULADO CON EL FIN DE QUE EL FARMACO SE LIBERE EN UNA CANTIDAD SUFICIENTE PARA MANTENER NIVELES SANGUINEOS TERAPEUTICAMENTE EFECTIVOS SUSTANCIALMENTE DURANTE 24 HORAS CUANDO SE ADMINISTRA CADA DIA EN UNA TOMA DIARIA. UNA SEGUNDA PARTE DEL NAPROXENO FORMULADO QUE SIRVE PARA QUE SE LIBERE EL FARMACO INMEDIATAMENTE DESPUES DE SU ADMINISTRACION, CON EL FIN DE OBTENER UNA RESPUESTA TERAPEUTICA RELATIVAMENTE INMEDIATA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE14990A IE66933B1 (en) | 1990-01-15 | 1990-01-15 | Controlled absorption naproxen formulation for once-daily administration |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2075338T3 true ES2075338T3 (es) | 1995-10-01 |
Family
ID=11007725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91300243T Expired - Lifetime ES2075338T3 (es) | 1990-01-15 | 1991-01-14 | Formulacion de naproxeno, de absorcion controlada, para administracion una vez al dia. |
Country Status (15)
Country | Link |
---|---|
US (1) | US5637320A (es) |
EP (1) | EP0438249B1 (es) |
JP (1) | JP3157182B2 (es) |
AT (1) | ATE126055T1 (es) |
AU (1) | AU639519B2 (es) |
CA (1) | CA2034096C (es) |
DE (1) | DE69111832T2 (es) |
DK (1) | DK0438249T3 (es) |
ES (1) | ES2075338T3 (es) |
GR (1) | GR3017633T3 (es) |
IE (1) | IE66933B1 (es) |
IL (1) | IL96900A (es) |
NZ (1) | NZ236762A (es) |
PH (1) | PH30694A (es) |
ZA (1) | ZA91274B (es) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527545A (en) * | 1989-09-18 | 1996-06-18 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
IT1256651B (it) * | 1992-12-11 | 1995-12-12 | Giancarlo Santus | Composizione farmaceutica a rilascio controllato in sospensione liquida |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
WO1993017673A1 (en) * | 1992-03-03 | 1993-09-16 | Top Gold Pty., Limited | Sustained release analgesics |
US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5536505A (en) * | 1993-12-15 | 1996-07-16 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends |
US5523095A (en) * | 1993-12-15 | 1996-06-04 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
ES2322405T3 (es) | 1996-07-08 | 2009-06-19 | Penwest Pharmaceuticals Co. | Matriz de liberacion controlada para farmacos insolubles en dosis elevadas. |
US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
DE19715594A1 (de) * | 1997-04-15 | 1998-10-22 | Bayer Ag | Analgetika-Kombination |
DE69819351D1 (de) * | 1997-09-11 | 2003-12-04 | Nycomed Danmark As Roskilde | Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids) |
RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
NZ333474A (en) * | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
US20040259895A1 (en) * | 1998-05-28 | 2004-12-23 | Medical Research Institute | Oral formulation of lipid soluble thiamine and lipoic acid |
WO2000004879A1 (en) * | 1998-07-24 | 2000-02-03 | Andrix Pharmaceuticals, Inc. | Granule modulating hydrogel system |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
PL205109B1 (pl) * | 1998-11-02 | 2010-03-31 | Elan Pharma Int Ltd | Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie |
ATE391495T1 (de) | 1999-09-30 | 2008-04-15 | Penwest Pharmaceuticals Co | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe |
IL149352A0 (en) | 1999-10-29 | 2002-11-10 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
KR100574213B1 (ko) | 2000-01-27 | 2006-04-27 | 다나베 세이야꾸 가부시키가이샤 | 서방성 제제 및 그의 제조 방법 |
EP2295042A1 (en) | 2000-10-30 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10211289A1 (de) | 2002-03-14 | 2003-09-25 | Basf Ag | Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität |
US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
US20060039974A1 (en) | 2002-09-11 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
SI21301A (sl) * | 2002-09-11 | 2004-04-30 | LEK farmacevtska družba d.d. | Farmacevtska oblika z nadzorovanim sproščanjem |
SI1576138T1 (sl) | 2002-11-15 | 2017-07-31 | Idenix Pharmaceuticals Llc | 2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
BR0317275A (pt) * | 2002-12-11 | 2005-11-08 | Pfizer Prod Inc | Liberação controlada de uma substância ativa em um ambiente de gordura alta |
PT1575566E (pt) * | 2002-12-26 | 2012-03-29 | Pozen Inc | Formas de dosagem em multicamada contendo naproxeno e triptanos |
US20040228918A1 (en) * | 2003-01-02 | 2004-11-18 | Chih-Ming Chen | Granule modulating hydrogel system |
US20050095299A1 (en) * | 2003-10-30 | 2005-05-05 | Wynn David W. | Controlled release analgesic suspensions |
CA2569961A1 (en) * | 2004-06-10 | 2005-12-29 | Glatt Air Techniques, Inc | Controlled release pharmaceutical formulation |
US20080280973A1 (en) * | 2004-06-28 | 2008-11-13 | Wender Paul A | Laulimalide Analogues as Therapeutic Agents |
US20060078621A1 (en) * | 2004-10-13 | 2006-04-13 | Wedinger Robert S | Method of providing customized drug delivery systems |
WO2007011972A2 (en) * | 2005-07-19 | 2007-01-25 | Inverseon, Inc. | Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases |
ZA200801592B (en) * | 2005-07-20 | 2009-10-28 | Panacea Biotec Ltd | Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor |
ATE489079T1 (de) | 2005-12-29 | 2010-12-15 | Osmotica Kereskedelmi Es Szolgaltata Kft | Mehrschichtige tablette mit dreifacher freisetzungskombination |
BRPI0711228A2 (pt) * | 2006-05-26 | 2012-06-19 | Auspex Pharmaceuticals Inc | "composto, método de tratar um mamìfero que sofre de um doença ou de uma condição envolvendo as enzimas ciclooxiganase, composição farmacêutica, processo para e deuteração de um composto pelatroca de pelomenos um átomo de hidrogênio do dito composto com um átomo do deutério e processo para preparar m composto" |
WO2008011595A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
US20090104236A1 (en) * | 2007-10-18 | 2009-04-23 | Pharmaceutics International, Inc. | Pharmaceutical solid hybrids |
AU2008343787B2 (en) | 2007-12-28 | 2014-01-30 | Impax Laboratories, Llc | Controlled release formulations of levodopa and uses thereof |
US20090252791A1 (en) * | 2008-04-02 | 2009-10-08 | Venkata Nookaraju Sreedharala | Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug |
FR2930147B1 (fr) * | 2008-04-18 | 2013-02-08 | Flamel Tech Sa | Forme orale solide dotee d'un double profil de liberation |
EP2306998A4 (en) * | 2008-06-20 | 2011-06-15 | Alphapharm Pty Ltd | PHARMACEUTICAL FORMULATION |
CN101411702B (zh) * | 2008-11-29 | 2010-12-29 | 河南大学 | 盐酸奈福泮萘普生钠复方缓释制剂及其制备方法 |
KR101762453B1 (ko) * | 2009-01-22 | 2017-07-28 | 에봇 헬스케어 프라이베잇 리미티드 | 변시치료 약제학적 조성물 |
US20110052679A1 (en) * | 2009-08-25 | 2011-03-03 | Pharmaceutics International, Inc. | Solid naproxen concentrates and related dosage forms |
ES2614878T3 (es) * | 2010-06-01 | 2017-06-02 | Geistlich Pharma Ag | Métodos y composiciones para terapia farmacéutica oral |
KR101160645B1 (ko) * | 2010-11-12 | 2012-06-29 | (주)게임콘어뮤즈먼트 | 미니 앨범 제작 장치 |
US8986739B2 (en) | 2011-02-28 | 2015-03-24 | Nicholas V. Perricone | Treatment of urinary incontinence using nitrone spin traps |
EP2717860A4 (en) * | 2011-06-08 | 2014-11-05 | Sti Pharma Llc | FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION |
CN107898790B (zh) | 2011-11-30 | 2024-06-21 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
CN105658211A (zh) | 2013-10-07 | 2016-06-08 | 怡百克制药公司 | 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途 |
CN106414415A (zh) | 2014-03-14 | 2017-02-15 | 北卡罗来纳大学教堂山分校 | 用于抑制雄性生育力的小分子 |
US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
CN114796142A (zh) * | 2022-04-08 | 2022-07-29 | 黄山学院 | 萘普生胃漂浮片及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4571333A (en) * | 1983-06-14 | 1986-02-18 | Syntex (U.S.A.) Inc. | Controlled release naproxen and naproxen sodium tablets |
EP0147780A3 (en) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Drug delivery device |
US4867984A (en) * | 1984-11-06 | 1989-09-19 | Nagin K. Patel | Drug in bead form and process for preparing same |
EP0212745B1 (en) * | 1985-08-16 | 1991-04-10 | The Procter & Gamble Company | Drug particles having constant release |
IT1200178B (it) * | 1986-07-23 | 1989-01-05 | Alfa Farmaceutici Spa | Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica |
GB2194017B (en) * | 1986-08-06 | 1991-01-23 | Shimizu Construction Co Ltd | Device for suppressing vibration of structure |
IT1201136B (it) * | 1987-01-13 | 1989-01-27 | Resa Farma | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
IT1215726B (it) * | 1988-01-18 | 1990-02-22 | Alfa Wassermann Spa | Formulazioni galeniche a cessione programmata. |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
-
1990
- 1990-01-15 IE IE14990A patent/IE66933B1/en not_active IP Right Cessation
-
1991
- 1991-01-08 IL IL9690091A patent/IL96900A/en not_active IP Right Cessation
- 1991-01-10 PH PH41828A patent/PH30694A/en unknown
- 1991-01-11 AU AU69332/91A patent/AU639519B2/en not_active Expired
- 1991-01-14 ZA ZA91274A patent/ZA91274B/xx unknown
- 1991-01-14 AT AT91300243T patent/ATE126055T1/de not_active IP Right Cessation
- 1991-01-14 DK DK91300243.2T patent/DK0438249T3/da active
- 1991-01-14 NZ NZ236762A patent/NZ236762A/en unknown
- 1991-01-14 DE DE69111832T patent/DE69111832T2/de not_active Expired - Lifetime
- 1991-01-14 EP EP91300243A patent/EP0438249B1/en not_active Expired - Lifetime
- 1991-01-14 CA CA002034096A patent/CA2034096C/en not_active Expired - Lifetime
- 1991-01-14 JP JP07028191A patent/JP3157182B2/ja not_active Expired - Lifetime
- 1991-01-14 ES ES91300243T patent/ES2075338T3/es not_active Expired - Lifetime
-
1994
- 1994-04-14 US US08/227,566 patent/US5637320A/en not_active Expired - Lifetime
-
1995
- 1995-10-04 GR GR950402746T patent/GR3017633T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU639519B2 (en) | 1993-07-29 |
EP0438249B1 (en) | 1995-08-09 |
JPH04217918A (ja) | 1992-08-07 |
DE69111832D1 (de) | 1995-09-14 |
JP3157182B2 (ja) | 2001-04-16 |
IE66933B1 (en) | 1996-02-07 |
NZ236762A (en) | 1992-12-23 |
GR3017633T3 (en) | 1996-01-31 |
DE69111832T2 (de) | 1996-03-14 |
US5637320A (en) | 1997-06-10 |
CA2034096A1 (en) | 1991-07-16 |
CA2034096C (en) | 2002-03-26 |
IL96900A0 (en) | 1992-03-29 |
EP0438249A1 (en) | 1991-07-24 |
IL96900A (en) | 1995-12-31 |
IE900149A1 (en) | 1991-07-17 |
ZA91274B (en) | 1991-10-30 |
ATE126055T1 (de) | 1995-08-15 |
DK0438249T3 (da) | 1995-09-18 |
AU6933291A (en) | 1991-07-18 |
PH30694A (en) | 1997-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2075338T3 (es) | Formulacion de naproxeno, de absorcion controlada, para administracion una vez al dia. | |
ATE526950T1 (de) | Hydrocodon-formulierungen mit gesteuerter freisetzung | |
DK383987A (da) | Ny galeniske formuleringer med programmeret afgivelse indeholdende antiphlogistika | |
UA29563C2 (uk) | Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду | |
DK0642788T3 (da) | Tramadolsaltholdigt lægemiddel med forsinket frigivelse af aktivt stof | |
MY100721A (en) | Therapeutic agent. | |
DE69533492D1 (de) | Orale Metoprolol-Dosisform des Typs "einmal täglich" | |
DE68909772D1 (de) | Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe. | |
PT615754E (pt) | Formas solidas de administracao oral de libertacao controlada flupertina | |
ES2147788T3 (es) | 3,4-diarilcromanos para el tratamiento de la dermatitis. | |
MY124465A (en) | Reduction of infarct volume using citicoline | |
GB9108629D0 (en) | Heterocyclic pharmaceutical compounds,preparation and use | |
EP0302714A3 (en) | Pharmaceutical composition for treatment of bone-wasting diseases | |
ATE38151T1 (de) | Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung. | |
DK0647267T3 (da) | Opbevaring af stamceller | |
BE880648A (fr) | Nouvelles formes galeniques d'administration de medicaments par voie orale, aliberation programmee et leurs procedes de preparation | |
RU96113328A (ru) | Способ торможения фиброзообразования | |
DK0560207T3 (da) | Præparat til oral anvendelse baseret på ibuprofen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 438249 Country of ref document: ES |